10th Anniversary Drug Discovery 2016

Posters

Chris Morris
STFC
2West-Life: A Virtual Research Environment for Structural Biology
Mymoona Akhter
Faculty of Pharmacy, Jamia Hamdard
India
3Computational design and validation of some novel, non pteridine analogs as selective Mycobacterium tuberculosis dihydrofolate reductase inhibitorsors
M. Mumtaz Alam
Faculty of Pharmacy, Jamia Hamdard
India
4Novel pyrazole–pyrazoline hybrids as antimalarial agents: their synthesis and 3D-QSAR studies
Laura Aitken
University of St. Andrews
5The Identification and Characterisation of Small Molecule Human ABAD Inhibitors as Therapeutics in Alzheimer’s Disease
Kristian Bruce
GSK
6VST
Hayley Saunders
MRC Technology
7Identification and characterisation of novel positive allosteric modulators of the Dopamine D1 Receptor
Laurence Arnold
MRC Technology
8Development of disease modifying anti-osteoarthritis compounds targeting Matriptase
Sururat Adigun
MRC Technology
9Screening ubiquitinated MALT1 to identify novel inhibitors
Sandor Snoeijers
Pepscope BV
Netherlands
11Kinase Profiling using Peptide Arrays and Mass Spec as a Tool to Predict the Effect of Kinase Inhibitors on Patients
Sandor Snoeijers
Pepscope BV
Netherlands
12Kinase Profiling Using Peptide Arrays and Phosphoproteomics
Sandor Snoeijers
Pepscope BV
Netherlands
13Kinase Profiling Using Peptide Arrays and Phosphoproteomics
Sandor Snoeijers
Pepscope BV
Netherlands
14Kinase Profiling Using Peptide Arrays and Phosphoproteomics
Sandor Snoeijers
Pepscope BV
Netherlands
15Kinase Profiling Using Peptide Arrays and Phosphoproteomics
David McCoull
MRC Technology
16Screening for Inhibitors of CSF-1R – A Novel Target in the Treatment of Alzheimer’s Disease.
Vendela Parrow
Dep of Medical Sciences
Sweden
17SciLifeLab drug discovery
Apeksha Shrivastava
Jamia Hamdard
India
21Pharmacophore Modeling & Docking Studies of DPP-IV enzyme Inhibitors
Israa Al-ibadi
University of salford
22Selective Recruitment of Glucocorticoid Receptor By Non-Steroid Ligands: Molecular Study of Novel Anti-Cancer Therapies
Helen Plant
AstraZeneca Pharmaceuticals
23Evaluation of venoms as a source of novel ligands for drug discovery
Badri Ampolu
Sygnature Discovery
24Drug Discovery Approaches for Epigenetic Targets
Lauren Eades
ApconiX Ltd
26Delivering CiPA to the Client
Kevin Jones
Corning Life Sciences
Netherlands
27In Vitro Hepatotoxicity Profiling Using Corning® Epic® Label-Free Technology with Primary Hepatocytes, HepG2 Cells, and Corning HepatoCells
Kevin Jones
Corning Life Sciences
Netherlands
28Cancer Therapeutic Screening in Tumor Spheroids Co-Cultured with Fibroblast and Immune Cells using Corning® Spheroid Microplates
Kevin Jones
Corning Life Sciences
Netherlands
29Three Dimensional Hepatotoxicity Screening using Corning® HepatoCells, the Spheroid Microplate and the SCREEN-WELL® Hepatotoxicity library
Kevin Jones
Corning Life Sciences
Netherlands
30High Content Screening of Corning® HepatoCells for Hepatotoxicity
Eve Rogers
University of Liverpool
31Exploring the Potential of the Physico-Mechanical Environment and Circadian Timing in Adult Stem Cell Differentiation
Emma Shanks
CRUK Beatson Institute
32Iterative Data Multiplexing Identifies Therapeutic Candidates for Oral Squamous Cell Carcinoma
Nuno Alves
Stevenage Bioscience Catalyst
33DiscoverAssist
Nuno Alves
Stevenage Bioscience Catalyst
34DiscoverAssist
Jey Jeyakumar
Plasticell Ltd
35A stem cell screening platform for discovery of chondrogenic small molecules and their drug targets
Muhammad Awais
Liverpool University
36Development of Small Molecule Inhibitors of Cyclophilin D to Protect Mitochondrial Function ˗ Potential Use for the Treatment of Acute Pancreatitis
Roy Edward
BioStatus Limited
37Monitoring Cell Death in Real-Time/Time-Lapse Studies
Ruediger Bader
Hamamatsu Photonics UK Ltd
39Ca²⁺ mobilization assay to predict GPCR ligands safety profile in Cor.4U human cardiomyocytes
Simon Lydford
Molecular Devices (UK) Ltd
40Assessing 2D & 3D cellular responses with the EarlyTox suite of cell viability and apoptosis reagents for plate reader and imaging systems
Simon Lydford
Molecular Devices (UK) Ltd
41Morphometric Characterisation of Cancer Spheroid Cultures using 2D/3D Image Analysis & Confocal Imaging Techniques
Andrew Green
DiscoverX
42Profiling Compounds in Human Primary Cell BioMAP® Systems for Drug Discovery and Development in Cancer Immunotherapy
SHWETA SHARMA
Jamia Hamdard
India
43In-silico studies of novel, non-pteridine analogues as selective Mycobacterium tuberculosis dihydrofolate reductase inhibitors
Apeksha Shrivastava
Jamia Hamdard
India
44Drug Designing of novel DPPIV enzyme Inhibitors using Computer Aided Techniques
Martine Ballinger
MRC Technology
46Solving the screening bottleneck: 96-well format HT reformatting and expression of IgGs for screening.
Arune Balaikaite
MRC Technology
47T-cell epitopes, virus-like particles and extracellular loop fusions for challenging antibody generation
SUNIL KUMAR
SHOOLINI UNIVERSITY
India
48Immunostimulatory potential of a bioactive fraction (PBC) from Phyllostachys bambusoides in SRBC immunized balb/c mice
Cristina-Ileana Ureche
SIRION BIOTECH
Germany
51Improving in vivo Application Through High Quality Viral Vector Technologies – Purity, Concentration & Vector Design as Key for Successful AAV Experiments
Laurie Gordon
GSK
53A platform for measuring and understanding intracellular cell concentration
Joseph Bradley
Scitegrity Limited
54Automated detection and control of controlled substances
Adam Dickinson
Nexcelom BioScience
55A high-throughput image cytometry-based screening method for the detection of IL2-induced peripheral blood mononuclear cell-mediated cytotoxicity
Adam Dickinson
Nexcelom BioScience
56A high-throughput 3D tumor spheroid screening method for drug discovery using imaging cytometry.
Adam Dickinson
Nexcelom BioScience
57Comparison of label-free cell cytotoxicity image cytometric detection method to CellTiter-Glo®
Adam Dickinson
Nexcelom BioScience
58Real-time Caspase 3/7 measurement of suspension and adherent cells using the Celigo® image cytometer
Steve Brough
Key Organics
59Building a Diverse and Experimentally-Curated Fragment Library
Andrea Lindemann
InSphero AG
Switzerland
60Characterization and application of 3D Multi-donor Human Liver Microtissues for predictive DILI testing
Andrea Lindemann
InSphero AG
Switzerland
61A Novel Standardized In Vitro Islet Model System for Efficacy and Toxicity Testing in Pancreatic β-cells
John Cuff
AstraZeneca
63Compounds in the right place at the right time!
Sapna Desai
GSK
65Promiscuous Activation of the Mast-Cell Degranulation Receptor, Mrgprx2, Induces Adverse Histamine-Like Reactions in Clinically Relevant Species
Bill Primrose
Ripptide Pharma
67A chemoenzymatic route to novel macrocycles
J Malcolm Wilkinson
Kirkstall Ltd
68Organ on a chip : A Status Report on Worldwide Developments
Bryon Ricketts
Avacta Life Sciences Ltd
69Generation and Formatting of Affimer® Biotherapeutics for the Inhibition of the PD-L1/PD-1 Pathway
Chloe Koulouris
University of Sussex
72Characterisation of serine racemase as a novel approach to modulating NMDA receptor function
james bennett
University of Oxford
73Chemical Tools For Exploring the Biology of the Epigenetic Readers BRD9 and BRD7.
Thomas Christott
University of Oxford
75A Chemical Tool to investigate the biology of SMARCA and PB1(5)
Silvia Cirillo
Sheffield University
76De novo designed short antimicrobial peptide as a potential siRNA delivery vector targeting cancer cells
Steven van Helden
Pivot Park Screening Centre
Netherlands
77The European Lead Factory: an efficient open-innovation platform with unique screening capabilities
Mark Abbott
Peak Proteins Ltd.
78X-RAY CRYSTAL STRUCTURES OF HITS FROM A FRAGMENT BASED DISCOVERY PROGRAM ON EPIGENETICS TARGET BRD3
Thierry Calmels
Bioprojet biotech
France
79A Duplexed assay for measurement of GPCR mediated calcium signaling and PathHunter -arrestin recruitment from single well using FDSS/-cell functional drug screening system
Amaury Fernandez-Montalvan
Bayer
Germany
80Fast and Accurate Assessment of Binding Kinetics in HTS Format with kPCA and Genedata Screener
Michael Rogers
University of Liverpool
81Small molecule inhibitors for Cyclophilin D
Carol Trim
Canterbury Christ Church University
82The antimicrobial effects of animal venom
Danielle McCullough
Canterbury Christ Church University
83Targeting breast cancer signalling pathways with animal venoms
Astrid Noerenberg
upcyte technologies GmbH
Germany
84Driving primary liver cells into proliferation - the upcyte® technology
Jonas Stenberg
Ridgeview Instruments AB
Sweden
85Real-time interactions on living immune cells
Sarah Ash
AstraZeneca
86Development of a Co-culture Assay Amenable to HTS
Victoria Miller
University of Sussex
87Identification of Potent and Selective Inhibitors to Investigate the Role of the Epithelial Sodium Channels in Neurodegeneration
Muddasar Farooq
Sekisui XenoTech
88Evaluation of Ketoconazole and its Alternative Clinical CYP3A4/5 Inhibitors as Inhibitors of Drug Transporters: The In Vitro Effects of Ketoconazole, Ritonavir, Clarithromycin, and Itraconazole on 13 Clinically-Relevant Drug Transporters
Gina Washbourn
University of Liverpool
89The Synthesis and Biological Evaluation of Carbamoyl Triazoles as Potential Antituberculosis Protease Inhibitors
Mohd Fuad Rahmat Sam
University of Liverpool
90Human Cell Perfusion Bioreactor Systems Utilising Biomaterials to create 3D Tissue Analogs of Stem Cell Niches for the Production of Red Blood Cells
Friedrich Reinhard
GSK
Germany
91Two-dimensional thermal proteome profiling and chemoproteomics as orthogonal drug target profiling strategies
malcolm haddrick
AstraZeneca
92Characterisation of stem cell derived cardiomyocyte spheroids using the CardioExcyte platform
Qiuyu Wang
Manchester Metropolitan University
93Investigating the response of gastric cancer cells to arabinoxylan extracts in vitro
Yasmine Alsaidi
Royal Holloway University of London
94Affinity peptidomics and the selection of protein markers for the early non-invasive detection of breast cancer
Ingo Montenbruck
Proteros Biostructures
Germany
95Commonalities and differences in protein production, kinetic profiling and X-ray crystallography supporting drug discovery processes for biologicals versus small molecules
Giorgia Salvagiotto
Cellular Dynamics International, A FujiFilm Company
United States
96Human iPSC-derived Tissues as Novel Translational Models for Drug Discovery.
patrick courtney
tec-connection
Germany
97Recent developments in the Smart Laboratory Enabled by Standards in Laboratory Automation
Roslyn Lloyd
PerkinElmer
98Imaging in cancer immunology: Phenotyping of multiple immune cell subsets in-situ in FFPE tissue sections
Matt Vassey
Aurelia Bioscience
99Novel 3-D micro-scaffold platform: A paradigm shift for cell-based screening
Therese Dynes
AstraZeneca
100Accelerated plate generation for Screening assays and reduction in Design-Make-Test cycle timelines are facilitated by Automation and Process improvements in Compound Management
John Malone
CN BioInnovations
101A microfluidic, 3D cell culture system for the mechanistic investigation of liver diseases and determination of compound efficacy.
Peter Strapps
PerkinElmer
102Detection and Modulation of Extracellular Matrix Protein Deregulation in Human Prostate Carcinoma Cells Using AlphaLISA Technology.
Louise Healy
Aurelia Bioscience
103Macrophage responses under hypoxic conditions – a drug target for the discovery of anti-cancer agents?
Amy Prosser
Sygnature Discovery
1043D Cell Culture: A Valuable Tool For Drug Discovery
Paul McGillan
University of Liverpool
105Design, Synthesis and Biological Evaluation of Novel 7-Amino Pyrazolopyrimidine Anti-Bacterial Compounds for the Treatment of Onchocerciasis and Lymphatic Filariasis.
David Whalley
AstraZeneca Pharmaceuticals
106High-throughput determination of the binding kinetics of nuclear hormone receptor antagonists using TR-FRET
Monica Mantri
University of Oxford
107Screening for small molecule inhibitors of a cytoplasmic Terminal Uridylyl Transferase implicated in the modulation of Let-7 tumor suppressor miRNA
Aisha Alsfouk
Strathclyde University
108Development of selective IKKα inhibitors as a treatment for prostate cancer therapy
Andrew Brierley
AstraZeneca
109Increasing Assay Precision by the Evaluation and Mitigation of Systematic Discrepancies in Compound Dispenses Following a Comparison of Technology Platforms
Oliver Wehmeier
acCELLerate GmbH
Germany
110Testing Compounds for Drug Induced Phospholipidosis Using Assay Ready Cryopreserved HepG2 Cells
Donna Potts
Agilent technologies
111Antibody Characterization Enabled by Automated Affinity Purification, Deglycosylation, IdeS Digestion, and Reduction
Katie Duffell
University of Sussex
112Development of a Tool Inhibitor of GCN5 Towards the Treatment of ccRCC
Julie Rainard
University of Dundee, ESC Newhouse
113Showing target engagement for HTS hits with Microscale Thermophoresis
Kristian Bruce
GlaxoSmithKline
114Industrialising a Volatile Solvent Transfer (VST) method to incorporate un-weighable compounds into the GSK Screening collection
Md. Saiful Islam
University of Oxford
116Controversial Story of a Fe(II) and 2OG dependent Oxygenase, JmjD6
Jim Gallagher
University of Liverpool
United States
117Developing therapies for the iconic disease alkaptonuria (AKU)
Jim Gallagher
University of Liverpool
United States
118In vitro models of bone formation and bone resorption
Sharon Bahia
PHE Culture Collections
119The EBiSC Catalogue
Sharon Bahia
PHE Culture Collections
120Utilisation of iPSCs in Drug Discovery and Development
Fiona McCann
NDORMS, University of Oxford
121Localised inhibition of histone acetylation may offer a novel therapeutic strategy to down regulate the myofibroblast phenotype in Dupuytren’s disease
Daniel Martinez Molina
Pelago Bioscience AB
Sweden
122The Cellular Thermal Shift Assay (CETSA) - Label free, physiologically relevant target engagement measures in the intact cell
Chris Evans
TTP Labtech
124Eliminating the false negatives in ATP-luminescence cell health assays by the use of a phenotypic based approach.
Chris Evans
TTP Labtech
125A practical solution for phenotypic screening of a full compound library
Gareth Jones
TTP Labtech
126Enriched datasets from in-house compound libraries using direct dilution methods in 1536 well plates
Gareth Jones
TTP Labtech
127Low volume automated liquid handling for studying autophagic pathway, and cellular transduction in cancer cells
Sarah Payne
TTP Labtech
128Multiplexed cell and bead based assays in a no wash format for biologics screening and characterisation
Sarah Payne
TTP Labtech
129Beating Moore’s law but now what? Reduced sample prep cost for genetic analysis
Karl Syson
John Innes Centre
130Remodelling α-glucan pathways in Mycobacterium tuberculosis and identifying new drug targets
Adrian Kinkaid
MIP Diagnostics Limited
131Automatic Reactor for the Synthesis of MIP Nanoparticles
Francesco Canfarotta
MIP Diagnostics Limited
132Imprinted Polymeric Nanoparticles for Diagnostic Applications
Liz Quinn
Takara Bio USA, Inc.
France
133Footprint free genome editing via CRISPR/Cas9 and single cell cloning of human iPS cells
Michael Elser
Takara Bio Europe
France
134Novel miniprep system for rapid purification of recombinant proteins and antibodies on high-capacity membranes
Keisha Hearn
Astex Pharmaceuticals
135Generation and characterisation of crizotinib-resistant NSCLC models
Katie Chapman
Domainex
136An Important role for TBK1/IKKε in IP10 signalling: A potential intervention in COPD
Jana Wolf
Domainex
137Fragment screening against the lysine methyltransferase G9a using Microscale Thermophoresis
Cristina-Ileana Ureche
SIRION BIOTECH
Germany
138Optimization of in vitro gene therapies with LentiBOOSTTM, a novel clinical applicable adjuvant improving LV transduction efficiency in hematopoietic cells
Irene Hallyburton
University of Dundee
139DDD107498: A Preclinical Candidate for Malaria
Amanda Jones
PerkinElmer
141Setting up a 3D High Content Imaging Assay to study Cholestasis using the Opera Phenix High Content Screening System
Dale Athey
Orla Protein Technologies
142A protein-engineering approach to assay development for in-process analysis during antibody-drug conjugate manufacture: a proof of concept with trastuzumab
Michael Thomas
Drug Discovery Unit
143DDD853651; A Preclinical Candidate for the Treatment of Visceral Leishmaniasis
Priyanka Dutta-Passecker
Axol Bioscience Limited
144Serum-free Human iPSC-Derived Cardiomyocytes for in vitro testing
Priyanka Dutta-Passecker
Axol Bioscience Limited
145Implementation of High Throughput Screening on iPS cells
Jennifer Riley
University of Dundee
146Giving CYP the slip…Establishment of an in vitro CYP51 inhibition assay to prioritise new chemical entities for Chagas’ Disease.
Laura Turunen
FIMM
Finland
147Acoustic dispensing in development of personalized medicine drug sensitivity and resistance testing (DSRT) platform at FIMM
Richard Wall
University of Dundee
148Defining drug mechanism of action: leveraging phenotypic hits against kinetoplastids
Rachel Harvey
AstraZeneca
149An Evaluation of iPSC-CM Cell Lines for Calcium Imaging Cardiotoxicity Screening
Matthew Burnham
Astrazeneca
150Characterisation of stem cell derived cardiomyocyte spheroids using the CardioExcyte platform
Neil Mallon
Caltag Medsystems Ltd
151Identification of Biomarkers for Ovarian Cancer using xxpress® qPCR
Maja Petkovic
AMS Biotechnology (Europe) Limited
152Next generation high capacity DNA damage detection assay for chemotherapy and genotoxic compound screening
Ann Macdonald
Thermo Fisher Scientific
154A robust platform for generation and high throughput functional analysis of human iPSC-derived cardiomyocytes
Spencer Campbell
Bicycle Therapeutics
155Discovery and characterisation of a CAIX-targeted Bicycle-Drug Conjugate.
Peter Craggs
GSK
156Autofluorescent and Active – the Use of Fluorescence Lifetime Technology to Eliminate False Fluorescent Hits
Peter Craggs
GSK
157Long Fluorescence Lifetime or Label-free? An Evaluation of Fluorescence Lifetime Technology for High Throughput Screening
Roland Leathers
Thermo Fisher Scientific
Switzerland
158Profiling Inhibitors with Full-Length LRRK2 in both Biochemical & Cellular Formats
Valerie Legris
Electrospinning Company
159Growing hiPSC-derived cardiomyocytes on Mimetix scaffold improves their function
Lauri Paasonen
UPM-Kymmene Corporation
Finland
1603D cell culture, assay automation and 3D printing demonstrated with a novel xeno-free hydrogel derived from wood
Claire McWhirter
AstraZeneca
161Assay Design Impacts on Hits Found During Primary Screening
Martin Brown
AstraZeneca
162Investigating Alternative Pathway Mechanisms of AhR Antagonism
Roja Hadianamrei
University of Sheffield
163Short amphiphilic peptides as new tools for gene delivery
Margaret Huggett
DDU, University of Dundee
164Fragment Library Design, Synthesis & Expansion: Nurturing a Synthesis and Training Platform
Margaret Huggett
DDU, University of Dundee
165Small polar compound library for TB drug discovery
Margaret Huggett
DDU, University of Dundee
166Fragment Library Design, Synthesis & Expansion: Nurturing a Synthesis and Training Platform
Margaret Huggett
DDU, University of Dundee
167Small polar compound library for TB drug discovery
Margaret Huggett
DDU, University of Dundee
168Designing and building lead-like diversity libraries
Margaret Huggett
DDU, University of Dundee
169Identification and prioritisation of hits from whole cell phenotypic screening of Mycobacterium Tuberculosis in the context of treatment shortening
Tony Hope
Drug Discovery Unit
170Innovative Targets: The DDU Approach
Samantha Hitchin
Cancer Research UK Manchester Institute
171CRUK:MI Advancing Drug Discovery Through Partnership
Jennifer Bishop
Kirkstall
172Can Organ-on-a-Chip Replace Animal Testing of Drug and Chemical Safety?
Samantha Hitchin
Cancer Research UK Manchester Institute
173CRUK:MI Advancing Drug Discovery Through Partnership
Hinnah Campwala
Essen BioScience
174Continuous live-cell proliferation, clustering and viability assays for T-cells, PBMCs, monocytes and B-cells
Mike Kerins
Cambridge Bioscience
175Miniaturization Of Singulex® and Luminex® Multiplex Based Cytokine Assay With Wall Less 96 Well Plates
Mike Kerins
Cambridge Bioscience
176Immunotherapeutic Target Identification & Drug Screening Using Patient Tumour & Blood Samples Cultured Under Conditions That Replicate The Metastatic Niche
Louise Affleck
Cisbio Bioassays
France
179Sensitive detection of GPCR-mediated ERK1/2 phosphorylations in various cellular models with the HTRF® advanced phospho-ERK1/2 kit
Louise Affleck
Cisbio Bioassays
France
180HTRF® phospho-protein platform facilitates the dissection of signaling pathways involved in insulin resistance and metabolic disorders
Louise Affleck
Cisbio Bioassays
France
181Implement HTRF® phospho-protein assays at every step of the drug discovery process: from in vitro to in vivo models
Carl Jarman
Labcyte Inc.
United States
182Identification of PI3K inhibitors with an Automated Echelon Fluorescence Polarization Assay Using the Labcyte Access Workstation with Integrated Labcyte Echo 525 and 555 Liquid Handlers and the EchoQualified Reservoir
Daniella Steel
Horizon Discovery
183A generic strategy for CRISPR - Cas9-mediated gene tagging
Hannes Hahne
OmicScouts GmbH
Germany
184Identifying drug targets and target engagement markers using proteome-wide CETSA and ITDR
Gesa Rascher-Eggstein
Nanion Technologies GmbH
185Cardiac drug and safety screening platforms for the future: automated patch clamp, extracellular field potential and impedance approach
Emma Cains
Allergan Biologics
186Application of Automation/Technology for Improving Cell Line Development
Peter Djali
IntelliCyt Corporation
United States
187A High Throughput Screening Assay to Assess PD-LI/2 Antibody Checkpoint Inhibitors
Cleoper Paule
Charles River Discovery
188HTMS Screen for Enzyme Inhibitors Utilising the Apricot ADDA for On-Line Sample Desalting
Weili Li
University of Chester
189Investigating the response of gastric cancer cells to arabinoxylan extracts in vitro
Tristan Pritchard-Meaker
Axiogenesis AG
Germany
190Human iPSC-derived cardiomyocytes for HTS to assess acute as well as chronic drug-induced cardiotoxicity
Count: 167